An observational study in Human Papilloma Virus, Human Papilloma Virus Related Cervical Carcinoma and Cervical Carcinoma, sponsored by AML. Completed at 1 site in Belgium. Open to female participants aged 30 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by AML · Observational
This study evaluates the performance of HPV testing on vaginal self-collected samples obtained with the Abbott Multi-Collect device. The study compares HPV test results from self-collected vaginal samples with results from clinician-collected cervical samples in women aged 30 to 64 years who either participate regularly in cervical cancer screening or have not attended screening for at least 3 years. The goal is to determine whether self-sampling provides accurate detection of high-risk human papillomavirus (hrHPV) and could support broader participation in cervical cancer screening programs.
Human papillomavirus (HPV) testing is an important component of cervical cancer screening. Self-sampling may increase screening participation, particularly among women who do not regularly attend screening programs. The Multi-Collect Specimen Collection Swab (Abbott) is a self-sampling device that offers practical advantages for large-scale screening, including simplified sample handling and compatibility with automated laboratory workflows.
This single-center, observational, cross-sectional study evaluates the clinical performance of HPV testing on vaginal self-collected samples obtained using the Abbott Multi-Collect device. HPV test results from self-collected vaginal samples are compared with matched clinician-collected cervical samples obtained during the same visit. Samples are analyzed using the Alinity m HR HPV assay, the m2000 RealTime High Risk HPV Assay, and the RIATOL qPCR HPV genotyping assay.
The study includes women aged 30 to 64 years who either regularly participate in cervical cancer screening or have not attended screening for at least 3 years. The inclusion of screening non-attenders allows evaluation of test performance in a population that may particularly benefit from self-sampling approaches and provides a setting that reflects real-world implementation of HPV self-sampling.
The study aims to assess the relative clinical accuracy of HPV testing on self-collected versus clinician-collected samples and to evaluate agreement between different HPV assays. The findings are intended to support the clinical validation of the Abbott Multi-Collect device for vaginal self-sampling as a tool to help expand access to cervical cancer screening.
Women attending a participating gynecology practice were recruited for this study. The population included women from a routine cervical cancer screening setting and women who had not recently participated in cervical cancer screening.
Exclusion Criteria:
Women aged 30 to 64 years who regularly participate in cervical cancer screening and had a negative high-risk human papillomavirus (hrHPV) result at their previous screening within the past 3 years.
Device: Abbott Multi-Collect Specimen Collection Swab
Women aged 30 to 64 years who did not participate in cervical cancer screening during the previous 3 years or longer.
Device: Abbott Multi-Collect Specimen Collection Swab
Vaginal self-sampling device used for collection of self-collected vaginal specimens for high-risk human papillomavirus testing.
Relative Sensitivity and Specificity of High-Risk HPV Testing on Self-Collected Versus Clinician-Collected Samples
Relative sensitivity and specificity of high-risk human papillomavirus (hrHPV) testing on vaginal self-collected samples compared with matched clinician-collected cervical samples using the Alinity m HR HPV assay, m2000 RealTime High Risk HPV Assay, and RIATOL qPCR HPV genotyping assay.
Time frame: From enrollment through completion of protocol-defined follow-up, up to 12 months
Agreement Between High-Risk Human Papillomavirus Assays
Concordance of high-risk human papillomavirus (hrHPV) test results between the Alinity m HR HPV assay, m2000 RealTime High Risk HPV Assay, and RIATOL qPCR HPV genotyping assay on vaginal self-collected samples.
Time frame: At enrollment
Absolute Sensitivity and Specificity for Detection of CIN2+
Absolute sensitivity and specificity of high-risk human papillomavirus testing on self-collected vaginal samples and clinician-collected cervical samples for the detection of underlying cervical intraepithelial neoplasia grade 2 or worse (CIN2+).
Time frame: From enrollment through completion of protocol-defined follow-up, up to 12 months
Beta-Globin Positivity Rate
Positivity rates of the beta-globin sample adequacy control in self-collected vaginal samples and clinician-collected cervical samples
Time frame: At enrollment
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.